CAS 879507-25-2

Formel: C25H17F6N5O

InChl: InChI=1S/C25H17F6N5O/c1-14-4-5-19(12-21(14)36-23-33-8-6-20(35-23)15-3-2-7-32-13-15)34-22(37)16-9-17(24(26,27)28)11-18(10-16)25(29,30)31/h2-13H,1H3,(H,34,37)(H,33,35,36)

InChI Key: LCPGCGAJBOWMIP-UHFFFAOYSA-N

SMILES: CC1=C(C=C(C=C1)NC(=O)C2=CC(=CC(=C2)C(F)(F)F)C(F)(F)F)NC3=NC=CC(=N3)C4=CN=CC=C4

AN-019

CAS: 879507-25-2

AN-019

Formel: C₂₅H₁₇F₆N₅O

Reinheit: 99.5%

Molekulargewicht: 517.43

Ref: 54-BUP07896

Nrc-AN-019

CAS: 879507-25-2

Formel: C₂₅H₁₇F₆N₅O

Molekulargewicht: 517.4258

Ref: IN-DA01ENVW

NRC-AN-019

CAS: 879507-25-2

NRC-AN-019 is an imatinib-resistant drug that belongs to the class of bcr-abl inhibitors. It has been shown to be effective in women with metastatic breast cancer and who are resistant to lapatinib and imatinib. NRC-AN-019 is a polymeric matrix that contains epidermal growth factor (EGF) and is designed for topical administration. The drug binds to the receptor tyrosine kinase erbB2, which prevents it from binding with the epidermal growth factor receptor (EGFR). This leads to suppression of cellular proliferation, differentiation, and angiogenesis. NRC-AN-019 also has pharmacokinetic properties that allow for escalation of dosage without significant toxicities or side effects.

Formel: C₂₅H₁₇F₆N₅O

Reinheit: Min. 95%

Molekulargewicht: 517.4 g/mol

Ref: 3D-EKB50725

AN-019

CAS: 879507-25-2

AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.

Formel: C₂₅H₁₇F₆N₅O

Reinheit: 99.96%

Farbe und Form: Yellow Solid

Molekulargewicht: 517.43

Ref: TM-T26625